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Background: Immune-checkpoint (IC) inhibitors have revolutionized the treatment of
multiple solid tumors and defined lymphomas, but they are largely ineffective in acute
myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not
efficacious is not well-understood but it may be due to the contribution of different IC
ligand/receptor interactions that determine the function of T cells in AML.
Methods: To analyze the interactions of IC ligands and receptors in AML, we performed a
comprehensive transcriptomic analysis of FACS-purified leukemia stem/progenitor cells
and paired bone marrow (BM)-infiltrating CD4+ and CD8+ T cells from 30 patients with
AML. The gene expression profiles of activating and inhibiting IC ligands and receptors
were correlated with the clinical data. Epigenetic mechanisms were studied by inhibiting
the histone deacetylase with valproic acid or by gene silencing of PAC1.
Results:We observed that IC ligands and receptors were mainly upregulated in leukemia
stem cells. The gene expression of activating IC ligands and receptors correlated with
improved prognosis and vice versa. In contrast, the majority of IC receptor genes were
downregulated in BM-infiltrating CD8+ T cells and partially in CD4+ T cells, due to
pathological chromatin remodeling via histone deacetylation. Therefore, treatment with
histone deacetylase inhibitor (HDACi) or silencing of PAC1, as a T cell-specific epigenetic
modulator, significantly increased the expression of IC receptors and defined effector
molecules in CD8+ T cells.
Conclusions: Our results suggest that CD8+ T cells in AML are dysfunctional mainly due
to pathological epigenetic silencing of activating IC receptors rather than due to signaling
by immune inhibitory IC receptors, which may explain the limited efficacy of antibodies that
block immune-inhibitory ICs in AML.
Keywords: acute myeloid leukemia, immune-checkpoints, immunotherapy, leukemia stem cell (LSC), CD8+ T cell,
CD4+ T cell, epigenetics (chromatin remodelling), histone (de)acetylationMay 2021 | Volume 11 | Article 6634061
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Acute myeloid leukemia (AML) is a hematologic malignancy
with a poor clinical prognosis. It arises from clonal expansion of
oncogene-transformed hematopoietic stem and progenitor cells,
known as leukemia stem cells (LSCs) (1). LSCs are therapy
resistant and evade direct killing by immune cells due to
diverse escape mechanisms. Therefore, LSCs are the leading
cause of relapse after initial successful chemotherapy (2).
Immune cells are part of the bone marrow (BM)
microenvironment and interact with the leukemia stem/
progenitor cells. Clinical observations and experimental
evidence suggest that myeloid leukemia is regulated by the
immune system (3). Tumor cells, including LSCs, can suppress
effective tumor-specific T cell responses. LSCs escape the
immune control by natural killer (NK) cells and CD8+ T cells
through the expression of immune-inhibitory molecules by
downregulating of critical molecules/pathways involved in
immune recognition, or by the expression of “don’t eat me”
signals, such as CD47 (4). Immune-checkpoints (ICs) are
essential regulators of the immune system, through activation
(stimulatory checkpoint molecules) or inhibition (inhibitory
checkpoint molecules) of immune cells (5, 6). The balance
of stimulatory and inhibitory ligand/receptor interaction
determines the amplitude and quality of the antigen-specific
immune responses (5). The generation of immune-checkpoint
inhibitors (ICIs) that blocks the inhibitory IC receptors, such
as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or
programmed cell death protein 1 (PD-1), has revolutionized
the treatment of different solid tumors and lymphomas
(7) . In contrast , blocking ICs in the treatment of
leukemia seems less effective (8–10). This is potentially due to
BM-infi l trat ing T cel ls expressing other inhibitory
receptors, such as T cell immunoglobulin and mucin-domain
containing-3 (TIM-3) and Lymphocyte-activation gene 3
(LAG-3) (11). Indeed, understanding the expression signature
of ICs on leukemia stem/progenitors and paired lymphocytes
in the BM is crucial for the development of novel
immunotherapy approaches.
In the present study, we performed a comprehensive
expression analysis of important IC ligand/receptor pairs in
AML stem and progenitor cells in parallel with paired BM-
infiltrating lymphocytes. We observed that gene expression of IC
ligands and receptors were mainly upregulated in leukemia stem
and progenitor cells (LSPCs). A high gene expression of IC
ligands and receptors with an activation function or low gene
expression of IC ligands and receptors with inhibition function
in LSCs correlated with better overall survival. In contrast, the
majority of IC receptor genes were downregulated in BM-
infiltrating CD8+ T cell and partially in CD4+ T cells. We
identified pathological histone deacetylation as the main cause
for the downregulation of IC receptors in CD8+ and CD4+ T
cells. Therefore, treatment with histone deacetylase inhibitor
(HDACi) significantly increased the expression of IC receptors
on T cells in AML at both gene and protein levels. Furthermore,
the expression of the phosphatase PAC1, a key T cell-specificFrontiers in Oncology | www.frontiersin.org 2epigenetic modulator, negatively correlated with the expression
of IC receptors in T cells from AML patients. Consequently,
silencing of the PAC1 gene significantly increased the expression
of different ICs on T cells. These findings could have potential
implications for the design of immunotherapies that target AML
and/or AML LSCs.MATERIALS AND METHODS
Patients
Blood and BM aspirates from patients diagnosed with AML were
prospectively collected at the Department of Medical Oncology,
University Hospital Bern. Thirty patients were selected from this
repository based on the FACS immune-phenotype of the AML
cells and the risk category. Risk categories of AML patients were
determined according to the defined molecular profile of patients
(guidelines for Dutch-Belgian Hemato-Oncology Cooperative
Group (HOVON) and Swiss Group for Clinical Cancer
Research (SAKK)). BM aspirates performed as a staging
procedure in patients with lymphoma that did not have a
pathological infiltration in the aspirate nor the biopsy were
used as controls.
FACS-Purification of Stem/Progenitors
and Paired CD4+/CD8+ T Cells
LSCs were defined as CD45+Lin-CD90-CD38-CD34+, leukemic
progenitor cells (LPCs) as CD45+Lin-CD90-CD38+CD34+,
hematopoietic stem cells (HSCs) as CD45+Lin-CD90+CD38-
CD34+ and normal progenitors (HPCs) as CD45+Lin-
CD90+CD38+CD34+ . CD4+ T l ymphocy t e s we r e
CD45+Lin+CD4+. CD8+ T lymphocytes were CD45+Lin+CD8+.
Lineage positive cells were defined by the expression of CD2,
CD3e, CD14, CD16, CD19, CD56 or CD235. All cell populations
were FACS-purified according to their immunophenotype using
a FACS ARIA III (BD Biosciences, USA).
Antibodies and Flow-Cytometry
aCD2-biotin (clone: RPA-2.10), aCD14-biotin (clone: HCD14),
aCD16-biot in (c lone : 3G8) , aCD19-biot in (c lone :
561), aCD235a-biotin (clone: HIR2), aCD3-biotin (clone:
OKT3a), aCD34-APC (clone: 561), aCD38-PE/Cy7 (clone:
HIT2), aCD4-APC/Cy7 (clone: RPA-T4), aCD8a-Pacific Blue
(clone: RPA-T8), aCD90-PerCP/Cy5.5 (clone: 5E10), aCD272-
FITC (aBTLA; clone: MIH26), aIgG2-FITC (clone: MOPC-
173), aCD200R-PE (clone: OX-108), aIgG1-PE (clone:
MOPC-21), aCD160-PerCP/Cy5.5 (clone: BY55), aIgM-
PerCP/Cy5.5 (clone: MM-30), aCD96-APC (clone: NK92.39),
aIgG1-APC (MOPC-21), aCD28-PE/Cy7 (clone: CD28.2),
aIgG1-PE/Cy7 (MOPC-21) and aStreptavidin-FITC were from
BioLegend, USA. aCD45-PE (clone: HI30) was from
eBioscience, USA. aIgG1-PE (clone: IS11-12E4.23.20) was
from Miltenyi Biotec, Germany. Samples were analyzed on BD
LSRFortessa™ (BD Biosciences, USA). Data was analyzed using
FlowJo software v.10.7 (FlowJo, LLC, USA).May 2021 | Volume 11 | Article 663406
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLMolecular Profiling
To analyze the interactions of IC ligands and receptors in AML,
we performed a detailed transcriptomic analysis in FACS-
purified leukemia stem/progenitor cells and paired CD4+ and
CD8+ T cells from 30 patients with AML and seven controls. In
total, 148 samples from 30 AML patients and seven controls were
analyzed using the human expression array “GeneChip®Human
Transcriptome Array 2.0 (HTA 2.0)” (Affymetrix Inc., USA).
The HTA 2.0 high-resolution array contains >6.0 million probes
covering both coding and non-coding transcripts. This provides
an in-depth insight into all coding and non-coding transcripts by
providing the coverage and accuracy required to detect all known
transcript isoforms produced by a gene. Of note, 146 samples
were selected for further analysis because of insufficient mRNA
amplification of two LSCs samples; due to limiting cell numbers
(patients #7 and #23).
Total RNA was extracted from the FACS-purified samples
using RNeasy Micro Kit (QIAGEN, Switzerland). The quantity
of extracted RNA was assessed by NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Inc., USA) and
by Bioanalyzer instrument using the RNA 6000 Pico Chip
(Agilent Technologies, Germany). The purified RNA was
quantified using the QuantiFluor RNA System (Promega,
USA). cDNA was synthesized using the GeneChip® Human
Transcriptome Pico Assay 2.0 (Affymetrix Inc., USA). The arrays
were hybridized with the biotin-labeled fragments using
GeneChip® Hybridization, Wash, and Stain Kit (Affymetrix
Inc., USA), and rotated in the hybridization oven for 48 hours
at 45°C and 60rpm. The arrays were washed and stained with a
streptavidin phycoerythrin conjugate on a GeneChip Fluidics
450 Workstations and scanned on a GeneChip Scanner 3000 7G
(Affymetrix Inc., USA). The expression data were acquired
using the Affymetrix GeneChip Operating Software (GCOS).
HTA annotations supplied by Affymetrix were used as
probe identifiers.
Transcriptomic Data Analysis
HTA data analysis was performed after Robust Multi-Array
Analysis (RMA), normalization, and log transformation.
Differentially expressed genes were defined according to the
following criteria: mean intensity greater than three, fold
change greater than 1.5 and P-values set to P<0.05. Principal
component analysis (PCA) was used to map the variations
among profiled samples. Unsupervised hierarchical clustering
of significant upregulated or downregulated genes was applied
using the standard Euclidean’s method and the heat maps were
generated according to the standard normal distribution of
the values.
Gene Expression Analyses Using
Quantitative RT-PCR (qPCR)
Several target genes were analyzed by real-time (qRT)-PCR.
cDNA was synthesized using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, USA). Primers were
designed for each gene by Primer3Plus (http://www.Frontiers in Oncology | www.frontiersin.org 3bioinformatics.nl/) or using Primerquest Software (Integrated
DNA Technologies). The complete sequences of used primers
are listed in Supplementary Table 1. qRT-PCR was performed
using FastStart Universal SYBR® Green 2X PCR Master Mix
(Roche, Switzerland). Raw values were normalized using the
geometric mean of reference genes (ACTB and GAPDH). qRT-
PCR reactions were performed in replicate using QuantStudio 3
System or ABI Prism 7500 Sequence Detection System
(Applied Biosystems).
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was performed using
GSEA software (Broadinstitute, Cambridge, USA). Enrichment
analysis was assessed for 30 IC ligand genes and 30 IC receptor
genes, respectively.
Histone Deacetylase Inhibition
FACS-purified CD4+ or CD8+ T cells were seeded in 48-well
culture plates at a density of 1×105 cells/well in IMDM media
(Sigma, Switzerland) supplemented with 10% FCS, 1% Pen-Strep
(Sigma, Switzerland), and hIL-2 5u/ml (Prospect). Cells were
treated with 1 mM sodium valproate (VPA) (Sigma, Switzerland)
or PBS. Then, 24h post treatment, total RNA was extracted and,
after cDNA synthesis, qRT-PCR was assessed for a panel of
selected genes, as described above. The CD4+ or CD8+ T cells
were harvested 48h post treatment and FACS-analyzed for the
protein expression of selected ICs.
Gene Silencing of PAC1 (DUSP2)
The human PAC1 gene was silenced in isolated human CD8+ or
CD4+ T cells from BM of AML patients using siRNA according
to the manufacturer’s instructions (Santa Cruz Biotechnology;
cat. sc-39004). Briefly, siPAC1 or siCtrl (scrambled control) was
mixed with Lipofectamine LTX (Thermo Fisher Scientific) in
serum-free media. Isolated CD8+ or CD4+ T cells were
subsequently treated with transfection complexes in the
presence of antibiotic-free growth medium supplemented with
10% FCS and hIL-2 5m/ml (Prospect) for 48h.
Statistical Analysis
Statistical analysis for qRT-PCR data and functional studies were
performed using GraphPad Prism (GraphPad Software, USA).
The Shapiro-Wilk test was used to assess the assumption of
normality in the datasets. Gene expression data were analyzed
using Student’s t-test (2-tailed). Survival time differences were
plotted using Kaplan-Meier curves and analyzed using the log-
rank test. The assigned cut-point for the survival analysis was
assessed using the X-Tile program based on the mean expression
of the immune-checkpoints gene panel. All P-values were
considered significant when P<0.05.
Data Availability and Resources
All transcriptomic data compiled in this study have
been deposited in NCBI GEO under the accession
codes: GSE117090.May 2021 | Volume 11 | Article 663406
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLRESULTS
IC Receptors and Ligands Are
Upregulated in AML Stem and Progenitors
The expression of 30 IC ligand/receptor pairs was analyzed in
FACS-purified stem and progenitor cells together with paired
lymphocytes (CD4+ and CD8+ T cells) from BM aspirates of 30
patients with newly diagnosed AML. Seven BM aspirates from
lymphoma patients without documented infiltration were used
as controls (Figure 1A). In total, 146 samples from different cell
populations were analyzed. The clinical and molecular
characteristics of AML patients are summarized in Table 1
and the complete characteristics of AML patients and controls
have previously been published by our group (12).
First, we analyzed the expression of 30 defined IC ligand/
receptor genes in LSCs and LPCs as well as in control
hematopoietic stem cells (HSCs) and control hematopoietic
progenitor cells (HPCs). We grouped the ligands and receptors
as activating or inhibitory ICs based on their main reported
function, although many ICs have activating or inhibitory
functions depending on the cell type and receptor signaling.
Principal component analysis (PCA) revealed a distinct gene
expression pattern between most LSCs/LPCs compared to the
control HSCs/HPCs (Figure 1B). LSCs/LPCs and HSCs/LPCs
expressed the majority of the analyzed IC ligand/receptor genes
(Figures 1C–F). Ten IC ligands and 11 receptors were
significantly upregulated in LSCs/LPCs compared to HSCs/
HPCs. The gene expression of IC ligands and receptors was
independent of the AML risk groups (Figure 2 and
Supplementary Figure 1). The number of upregulated IC
genes in LPCs was higher than in LCSs (Figures 1C, F and
Supplementary Figure 2, 3). Gene set enrichment analysis
(GSEA) of the 30 analyzed IC ligand/receptor pairs confirmed
the upregulation of IC ligands and receptors (Figures 1D, G).
Interestingly, many upregulated genes in LSCs/LPCs encode for
the IC ligands/receptors with an inhibitory function (e.g., CD200,
CD276, IDO1, PDCD1LG2, TDO2, VTCN1, CD96, CD160,
CTLA4 and HAVCR2). A high gene expression of IC ligands/
receptors with an activation function or a low expression of ICs
with inhibitory function in LSCs correlated with improved
overall survival (Figure 1E). A similar trend was observed for
IC genes expressed on LPCs without reaching significance
(Supplementary Figure 3B).
IC Ligands Are Upregulated While
Receptors Are Downregulated in
BM-Infiltrating T Cells
Next, we analyzed the IC gene expression profile of CD4+ and
CD8+ T cells in the BM (Figure 3). The PCA analysis revealed a
distinct gene expression pattern between BM-infiltrating CD4+
and CD8+ T cells in leukemia as compared to the controls
(Figure 3A). Six out of 30 IC ligand genes and three of 30 IC
receptor genes were differentially expressed in CD4+ T cells of
leukemia patients (Figures 3B, C and Supplementary Figure 4).
In CD8+ T cells from leukemia patients, 17 of 30 ligands and 10
of 30 receptors were differentially expressed. IC ligand genesFrontiers in Oncology | www.frontiersin.org 4were preferentially upregulated, whereas, the receptor genes were
mainly downregulated in CD8+ T cells from AML patients
(Figures 3D, E, Supplementary Figure 5). Similarly, a high
gene expression of ICs with either activating function or a low
expression of IC genes with inhibitory function in CD8+ T cells
of AML patients correlated with improved overall survival
(Figure 3F). In contrast, the expression of IC genes in CD4+ T
cells was not a prognostic marker (Supplementary Figure 4B).
IC Receptors in AML BM-Infiltrating
T Cells Are Silenced Due to Pathological
Histone Deacetylation
Since IC receptor genes were predominantly downregulated in
CD8+ T cells of AML patients, we postulated that this
phenomenon may potentially be due to chromatin remodeling.
Previously, we documented a general downregulated gene
signature in BM derived CD8+ T cells in AML and an
upregulation of genes regulating chromatin organization or
negatively regulating gene expression and transcription (12). In
addition, chromosomal position-based gene-mapping
(Karyogram) analysis predicted that downregulated genes were
mainly enriched in defined genome regions as indicative of
aberrant histone deacetylation (12). In CD8+ T cells,
Karyogram analysis of IC receptors revealed that the majority
of downregulated IC receptor genes (BTLA, CD27, CD96, CD160,
CD200R1, and CD244) were localized in the predicted hotspots
for histone remodeling. In contrast, upregulated IC receptor
genes or those that were similarly expressed in AML patients and
controls, were distributed in other chromosomal regions
(Figure 4A).
To assess the impact of histone deacetylation on the gene
expression of downregulated IC receptors at functional levels,
FACS-purified CD8+ or CD4+ T cells from different AML
patients with downregulated gene expression of IC receptors
were treated with the histone deacetylase inhibitor (HDACi),
Valproic acid (VPA). Treatment with VPA significantly
increased the expression of IC receptors at both mRNA and
protein levels (Figures 4B, C, Supplementary Figure 6). In
addition, VPA treatment increased the gene expression of
granzyme A (GZMA), granzyme B (GZMB), interferon-gamma
(IFNG), and PDCD1 in CD8+ T cells (Figure 4D).
The phosphatase of activated cells 1 (PAC1; also known as
dual specificity phosphatase 2, DUSP2) was recently identified as
a T cell suppressor and a crucial epigenetic immune regulator
that acts via the histone-deacetylase complex leading to
chromatin remodeling of effector T cells (13). In our AML
patient cohort, PAC1 gene expression negatively correlated
with the gene expression of downregulated IC receptors,
particularly in CD8+ T cells and partially in CD4+ T cells
(Figures 5A, B). To assess the functional role of PAC1 on the
expression of downregulated IC receptors, we silenced the PAC1
gene in FACS-purified CD8+ or CD4+ T cells from AML patients
with downregulated gene expression signature of IC receptors.
Knockdown of PAC1 gene resulted in a significant upregulation
of different IC genes (Figures 5C, D). Importantly, in CD8+ T
cells, knockdown of PAC1 led to a significant upregulation ofMay 2021 | Volume 11 | Article 663406







FIGURE 1 | Expression of ICs in AML stem and progenitor cells. (A) Experimental setup. Leukemia stem or progenitor cells (LSCs/LPCs), control hematopoietic
stem or progenitor cells (HSCs/HPCs), and paired T cells were FACS-purified. (B) PCA of LSCs/HSCs and LPCs/HPCs from AML patients and controls. (C) Gene
expression patterns of ICs in AML LSCs compared to controls (30 ligands and 30 receptors). Dot plots show the gene expression profiles (red arrows showing
upregulated ICs and blue arrows indicating downregulated ICs; Fold difference ≥ 1.3). Heatmaps illustrate the expression patterns in respective AML risk groups.
(D) Gene set enrichment analysis (GSEA) representing the normalized enrichment score (NES) of IC gene sets on LSCs (AML vs. ctrl). (E) Kaplan–Meier plots of
overall survival (OS) for AML patients in the study cohort according to the gene expression signature of activating or inhibitory ICs in LSCs. (F) Gene expression
patterns of ICs in AML LPCs compared to controls. Dot plots show the gene expression profiles and heatmaps illustrate the expression patterns in respective AML
risk groups. (G) GSEA representing the NES of IC gene sets on LPCs (AML vs. ctrl). Statistics: student’s t-test and log-rank test. *P < 0.05, **P < 0.01, ***P < 0.001.Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6634065
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLGZMB and IFNG genes suggesting an improved functionality of
CD8+ T cells (Figure 5E).
These findings indicate that silenced expression of IC
receptors in AML BM-infiltrating T cells is mainly due to
pathological histone deacetylation and can be reversed by
treatment with deacetylation inhibitor agents or by blocking
the T cell-specific epigenetic regulator PAC1 (Figure 5F).DISCUSSION
Dysfunctional and/or immunosuppressive T cells in AML have
been previously described, specifically in peripheral blood (14–
18). AML LSCs express different co-stimulatory and co-
inhibitory ligands, and the efficacy of ICIs is identifiably lower
in leukemia than in solid tumors (11). Although the role of the
PD-1/PD-L1 pathway in immune evasion has been reported in
several murine leukemia models (19–21), clinical trials with PD-
1 blocking antibodies as monotherapy have revealed a low
response rate in patients. Several studies with different PD-1
blocking antibodies are ongoing, either at a time point when
most of the leukemia bulk has been eliminated prior to
chemotherapy, in combination with chemotherapy, or in
combination with hypomethylating agents that upregulate the
expression of PD-L1 on leukemia cells (11). In addition, tri-
specific antibodies that combine T cell redirection to CD33
expressing myeloid cells together with an anti-PD-L1 partFrontiers in Oncology | www.frontiersin.org 6demonstrate enhanced cytotoxicity against primary AML cells
in vitro (22). Non responding patients to PD-1 blockade, often
co-express other immune inhibitory receptors, such as TIM-3
and LAG-3 on effector T cells (11). Furthermore, AML blasts
expressing T cell inhibitory ligands B7-H3, galectin-9 (Gal-9),
and CD200. The expression of most of these ligands is not
limited to a given FAB subtype. However, TP53-mutated AML
more frequently expresses PD-L1 and 4-1BBL (23).
Leukemia cells do not only express ligands for immune-
checkpoints that regulate the leukemia-specific immune
response but also express immune-checkpoint receptors (24).
This implies that niche cells (including immune cells) that
express ligands for these co-stimulatory or co-inhibitory
receptors, may regulate LSC function (25). The exact
mechanism of how the expression of these co-stimulatory
molecules induces AML disease progression and poor
prognosis remains unclear. To analyze the interactions of IC
ligands and receptors in AML, we performed a detailed gene
expression analysis in well-defined samples of FACS-purified
leukemia stem/progenitor cells and paired BM-infiltrating CD4+
and CD8+ T cells from AML patients and controls.
Our data indicate that ICs are dysregulated on AML LSCs/
LPCs as well as in BM-infiltrating T cells. This promotes multiple
interactions between the individual cell populations, leukemia,
and immune cells. IC receptor and ligand genes were mainly
upregulated in LSCs and LPCs. Some of these ICs, such as
CTLA-4, LAG-3, CD27, LTbr, TIM-3, and its ligand Gal-9 orTABLE 1 | Clinical and molecular characteristics of AML patients in the present study.
Patient ID Sex Age (year) AML risk category Molecular diagnostic Cytogenetics BMblasts (%)
AML#1 M 46 Adverse FLT3-ITD Normal 95
AML#2 M 66 Adverse FLT3-ITD Normal 90
AML#3 F 49 Adverse FLT3-ITD Normal 97
AML#4 M 76 Intermediate FLT3-ITD, NPM1 Normal 70
AML#5 F 65 Intermediate FLT3-ITD, NPM1 Normal 90
AML#6 F 71 Intermediate FLT3-ITD, NPM1 Normal 60
AML#7 F 63 Favorable NPM1 Normal 90
AML#8 M 54 Favorable NPM1 Normal 20
AML#9 F 80 Favorable NPM1 Normal 90
AML#10 F 66 Favorable AML1-ETO t(8;21) 90
AML#11 F 40 Favorable AML1-ETO t(8;21) 70
AML#12 M 69 Adverse MLL-Rearrangement Trisomy 11q23.3 80
AML#13 M 39 Intermediate MLL-Rearrangement t(11;17)(q23; q12-21) 95
AML#14 M 32 Favorable CBFB/MYH11 inv(16) 90
AML#15 M 73 Favorable CBFB/MYH11 inv(16) 90
AML#16 F 30 Favorable CEPBA Normal 40
AML#17 F 46 Intermediate JAK2 Trisomy 8 90
AML#18 F 57 Adverse Normal CK 40
AML#19 M 79 Adverse Normal t(4;8)(q21;q22), del(9)(p21), del(18)(q21) 95
AML#20 M 60 Intermediate Normal Trisomy 13 Trisomy 21 80
AML#21 M 70 Intermediate Normal Normal 80
AML#22 M 69 Adverse Others Monosomy 7 (total), 5q31.2 and 5q33 85
AML#23 M 59 Intermediate Normal Normal 70
AML#24 F 40 Adverse Others CK 90
AML#25 M 69 Adverse Normal CK with Monosomy 5q,7, 14, 15, 16, 18 80
AML#26 M 40 Favorable Normal t(15,17) 90
AML#27 F 75 Intermediate Normal Normal 20
AML#28 M 59 Adverse Normal Monosomy 7q31.2 80
AML#29 F 20 Intermediate Normal Normal 60
AML#30 M 70 Intermediate Normal Normal 70May 2021 | Volume 11 |BM, bone marrow; CK, complex karyotype.Article 663406
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shown to expand LSCs and contribute to disease progression
(26–28). In the present study, we did not analyze the role of
individual ICs but rather grouped the ligands and receptors as
activating or inhibitory ICs based on their main reportedFrontiers in Oncology | www.frontiersin.org 7function, mainly in T cells (5). However, the function of ICs
activation vs. inhibition depends on the cell type and the context
of the signaling (5, 29, 30). Interestingly, the gene expression of
activating IC ligands and receptors correlated with improved
survival of AML patients, whereas, the gene expression ofA
B
FIGURE 2 | IC expression in LSCs in AML patients with different molecular or cytogenetic aberrations. (A) Heatmap indicating the gene expression profile of 30 IC
ligands. (B) Heatmap indicating the gene expression profile of 30 IC receptors.May 2021 | Volume 11 | Article 663406






FIGURE 3 | Expression of ICs in BM-derived T cells. (A) PCA of CD4+ or CD8+ T cells from AML patients and controls. (B) Gene expression patterns of ICs in CD4+
T cells from leukemia patients compared to controls (30 ligands and 30 receptors). Dot plots indicate the gene expression profiles (red arrows showing upregulated
ICs and blue arrows indicating downregulated ICs; Fold difference ≥ 1.3). Heatmaps illustrated the gene expression patterns in respective AML risk groups.
(C) GSEA representing the normalized enrichment score (NES) of IC gene sets on CD4+ T cells (AML vs. ctrl). (D) Gene expression patterns of ICs in CD8+ T cells
from leukemia patients compared to controls. Dot plots show the gene expression profiles and heatmaps illustrate the expression patterns in respective AML risk
groups. (E) GSEA representing the NES of IC gene sets on CD8+ T cells (AML vs. ctrl). (F) Kaplan–Meier plots of overall survival (OS) for AML patients in the study
cohort according to the gene expression signature of activating or inhibitory ICs in CD8+ T cells. Statistics: student’s t-test and log-rank test. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, ns, not significant.Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6634068
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLinhibitory IC ligands or receptors was a negative prognostic
factor. The comparison to control HSC/HSPCs revealed that
mainly inhibitory ligand genes were upregulated. This suggests
that the sum of the inhibitory signals provided to T cells
diminishes the anti-leukemic immune response. This
inhibitory microenvironment in the bone marrow may be
further increased by the expression of most of the inhibitory
IC ligands, including, PD-L1 on BM-infiltrating CD8+ T cells.Frontiers in Oncology | www.frontiersin.org 9However, we observed a strong downregulation of most IC
receptor genes on BM-infiltrating CD8+ T cells, possibly
reducing the ligand/receptor interaction. PD1 seems to be one
exception and Daver et al. recently reported that the frequency of
PD1+/CD8+ T cells was significantly higher in bone marrow
aspirates (BMAs) of patients with newly diagnosed AML than in
healthy BMAs as controls. A similar but not significant difference
was observed for the frequency of OX40+/CD8+ T cells (23).A
B C D
FIGURE 4 | Epigenetic silencing of immune-checkpoint receptors in BM-infiltrating T cells. (A) Chromosomal position-based gene-mapping (Karyogram) analysis
indicating the localization of 30 IC receptors. Black vertical lines on the chromosomal surfaces are indicating the previously identified downregulated genes in CD8+ T
cells that were enriched in particular chromosomal regions mainly due to histone deacetylation (12). Black boxes indicate the chromosomal regions containing at
least 5 downregulated genes located in a genome distance with less than 5 Mbp from each other, as potential hotspots for the histone remodeling. The 30 newly
analyzed IC receptors of AML CD8+ T cells are plotted and highlighted with colored arrows in the karyogram to assess their chromosomal localizations
(downregulated ICs: blue arrows; upregulated ICs: red arrows; ICs with no change: gray arrows). (B) Gene expression profile of 10 downregulated IC receptors in
CD8+ or CD4+T cells of AML patients upon treatment with VPA. The fold differences were calculated as the ratio of VPA vs. vehicle conditions (n=5 AML patients per
each group of CD8+ T cells and n=4 AML patients per each group of CD4+ T cells). (C) Surface protein expression of IC receptors on CD8+ or CD4+ T cells of AML
patients. Delta MFI: MFI staining - MFI isotype (n=4 AML patients per group). (D) Heatmap illustrates the expression patterns of three key genes regulating the
function of CD8+ T cells as well as PDCD1 gene expression, upon treatment with VPA (n=4 AML patients). Statistics: student’s t-test. *P < 0.05, **P < 0.01,
***P < 0.001.May 2021 | Volume 11 | Article 663406
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLComparably, some IC receptors, including PD-1, were
upregulated in CD4+ or CD8+ T cells of AML patients versus
healthy controls in the present study.
Different studies have demonstrated that aberrant epigenetic
alterations, such as histone remodeling and DNA methylation
play a crucial role in the dysregulation of ICs during
carcinogenesis (14, 15, 31). In addition, DNA hypomethylating
agents (HMAs) such as azacitidine and decitabine upregulate the
expression of PD-L1 in solid tumors (16) and AML (17) and
thereby dampen the anti-tumor immune response. A clinicalFrontiers in Oncology | www.frontiersin.org 10study testing the combination of azacytidine in combination with
the PD-1 blocking antibody nivolumab in the treatment of AML
resulted in an overall response rate of 33% (58% for the HMA-
naïve patients (18)). We recently documented that pathological
epigenetic alteration via histone deacetylation silences gene
expression in BM-infiltrating CD8+ T cells. This silenced gene
expression was a positive prognostic factor and CD8+ T cells
supported the maintenance and expansion of (12). This finding
was somewhat counterintuitive, as activated CD8+ T cells are
necessary to eliminate LSCs. The preferential downregulation ofA B
C D
E F
FIGURE 5 | Epigenetic silencing of immune-checkpoint receptors in T cells is modulated via PAC1. (A, B) Correlation analysis of the gene expression signature for
downregulated ICs vs. expression pattern of PAC1 gene, in CD8+ or CD4+ T cells respectively (n=30 AML patients). (C, D) Gene expression profile of 10
downregulated IC receptors in CD8+ or CD4+T cells of AML patients upon PAC1 gene silencing. The fold differences were calculated as the ratio of siPAC1 vs. siCtrl
(n=3 AML patients per each group of CD8+ or CD4+ T cells). (E) Expression profile of key effector molecules of CD8+ T cells upon PAC1 gene knockdown (n=3 AML
patients). (F) BM-infiltrating T cells in AML are dysfunctional due to a downregulation of activating IC receptors mainly via a pathologic epigenetic silencing through
histone deacetylation; ICR, immune checkpoint receptor; HDAC, histone deacetylase. Statistics: student’s t-test. *P < 0.05, **P < 0.01.May 2021 | Volume 11 | Article 663406
Radpour et al. Epigenetic Silencing of IC-Receptors in AMLIC receptors in AML BM-infiltrating CD8+ T cells suggests that
they are regulated by epigenetic mechanisms. This hypothesis
was strengthened by the preferential localization of the
downregulated IC receptors in predefined hotspots for
histone remodeling.
Histone deacetylase (HDAC) enzymes modulate maturation,
migration, and TCR signaling in T cells by mediating
the expression of essential transcription factors such as Tcf1
and Lef1 (32, 33). Treatment with HDACi enhances the anti-
tumor activity of cytotoxic T cells in different tumor types
(34). In addition, HDACi directly acts on tumor cells by
upregulating MHC class I molecules and indirectly by
eliminating myeloid-derived suppressor cells (35). Notably,
HDACis can increase the expression of immune-related
molecules in different cancer types (36, 37). In our study,
treatment with HDACi increased the gene expression of
defined IC receptors mainly in AML BM-infiltrating CD8+ T
cells and partially in CD4+ T cells.
Several studies have demonstrated that treatment with
HDACi dampens the anti-tumor immune response by
upregulation of PD-1 on T cells (38, 39). Thus, PD-1/PD-L1
blocking antibodies and HDACis have synergistic effects in the
treatment of different cancers (38, 39). Additionally, VPA
treatment blocked the function of myeloid-derived suppressor
cells and made tumor cells susceptible to anti-PD-L1
immunotherapy (40). Similarly, treatment with HDACi in our
study resulted in an upregulation of PDCD1 in CD8+ T cells,
suggesting an increased vulnerability to treatment with ICIs
The phosphatase PAC1 was recently identified as an
important mediator of T cell dysfunction in tumor infiltrating
lymphocytes (TILs) that act via histone deacetylation to reshape
chromatin accessibility during activation of effector T cells (13).
We observed a negative correlation of PAC1 expression with the
expression of the downregulated ICs in AML BM-infiltrating
CD8+ T cells. Silencing of PAC1 resulted in the upregulation of
different ICs and enhanced the expression of CD8+ T cell
effector molecules.
In summary, our results indicate that CD8+ T cells in AML
are dysfunctional due to a downregulation of activating IC
receptors rather than due to signaling by immune inhibitory
IC receptors. These findings may explain the limited efficacy of
antibodies that block immune-inhibitory ICs. Therefore,
treatment with HDACi or targeting of T cell-specific epigenetic
modulators may stimulate anti-tumor immunity by increasing
CD8+ T cell effector function in leukemia patients and restore the
susceptibility to treatment with IC blocking agents.Frontiers in Oncology | www.frontiersin.org 11DATA AVAILABILITY STATEMENT
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